PT - JOURNAL ARTICLE AU - Mills, Vanessa AU - Owens Tyson, Teresa AU - Helton, Rachel AU - Hill-Collins, Paula AU - Hubbard, Sarah AU - Scott, Anchi AU - Hickey, Jeff A. AU - Root, Brian E. AU - O’Brien, Rory AU - Conte, Jillian AU - Stanton, Jo-Ann L. AU - Chapman, Jeff D. TI - Usability and performance of the MicroGEM Sal6830™, an RT-PCR saliva-based point-of-care platform to detect SARS-CoV-2 in primary healthcare settings with non-laboratory trained operators AID - 10.1101/2023.01.01.22283267 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.01.22283267 4099 - http://medrxiv.org/content/early/2023/01/03/2023.01.01.22283267.short 4100 - http://medrxiv.org/content/early/2023/01/03/2023.01.01.22283267.full AB - The beginning of the COVID-19 pandemic demonstrated how few point-of-care diagnostic tools were available that could be safely and easily operated by healthcare workers with no laboratory training. The gold-standard test, and initially the only test, used RT-PCR with nasal pharyngeal swabs (NPS). Two issues quickly emerged: 1) RT-PCR required central laboratory processing leading to significant time delays and 2) NPS collection causes discomfort, is inappropriate for ongoing repeat sampling of individuals (e.g., frontline healthcare workers) and poses difficulty when obtaining samples from some sections of the population (e.g. some elderly and young children). The Sal6830™ platform is a fully self-contained, RT-PCR point-of-care device for detecting SARS-CoV-2 from saliva that takes less than thirty minutes to complete. In this study we tested the usability of the Sal6830™ platform by healthcare workers unfamiliar with the instrument at two community clinics: Care 4 U Community Health Center (Miami, Florida, USA) and St. Mary’s Health Wagon (Wise, Virginia, USA). Staff participated in three tests: 1) determining SARS-CoV-2 status from blinded positive and negative saliva samples, 2) a clinical study comparing SARS-CoV-2 detection with a comparator point-of-care technology from the same patient and 3) completing a survey designed to measure comfort and confidence using the Sal6830™ point-of-care device having received no training. Participants overwhelming found the Sal6830™ platform easy and intuitive to use, successfully called SARS-CoV-2 status of contrived, blinded samples and measured a 93.3% overall percent agreement when comparing patient samples across two point-of-care technologies.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: all support for work presented in this manuscript was provided by MicroGEM International PLC, including all funding, study materials, medical writing, article processing charges, etc; AS, JAH, JC, JDC, and BR hold stock in MicroGEM International PLC; JS, JDC and BR have pending patent applications; JS receives royalties from sales through the University of Otago benefit sharing scheme; AS, JAH, JC, JDC, RO, JS and BR are salaried employees of MicroGEM International PLC; Sal6830 development was supported by New Zealand grant MBIE UOOX1703 and the US NIH RADx program (2020); no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis study was funded by MicroGEM International PLCAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB 1313475 of Care 4 U Community Health Center gave ethical approval for this work IRB 1315538 of St Mary's Health Wagon gave ethical approval for the work. The IRB tracking number for this study was 2021278I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors